Meloxicam injection - Baudax Bio
Alternative Names: ANJESO; N-1539; NanoCrystal® meloxicamLatest Information Update: 28 Apr 2025
At a glance
- Originator Elan Drug Delivery Inc
- Developer Baudax Bio
- Class 2 ring heterocyclic compounds; Amides; Analgesics; Anti-inflammatories; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Postoperative pain
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for clinical-Phase-Unknown development in Postoperative-pain(In adolescents, In children) in USA (IV, Injection)
- 28 Dec 2022 Withdrawn for Postoperative pain in USA (IV)
- 22 Aug 2022 Baudax Bio receives notice of allowance for Meloxicam injection in USA